Silver Book Fact

t-PA cost savings

The total annual benefit to society from t-PA use in the United States is around $363 million—$60 million in direct cost savings to society plus an additional 7,510 QALYs. This means that t-PA saves $6,074 and adds 0.75 QALY per use.

Johnston, SC. The Economic Case for New Stroke Thrombolytics. Stroke. 2010; 41(10): S59-62. http://stroke.ahajournals.org/cgi/content/short/41/10_suppl_1/S59

Reference

Title
The Economic Case for New Stroke Thrombolytics
Publication
Stroke
Publication Date
2010
Authors
Johnston, SC.
Volume & Issue
Volume 41, Issue 10
Pages
S59-62
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Aspirin use in AFib patients
    Meta-analysis of a number of randomized controlled trials found that aspirin use in atrial fibrillation patients reduced stroke risk by an average 22%.  
  • Effect of optimal anticoagulation
    If 50% of atrial fibrillation patients who currently receive warfarin in routine medical care were optimally anticoagulated, 9,852 emboli would be prevented and $1.3 billion would be saved each year.  
  • Effects of optimal anticoagulation among AFib patients
    If 50% of individuals with atrial fibrillation who do not receive prophylaxis were optimally anti-coagulated, 19,380 emboli would be prevented and $1.1 billion would be saved each year.  
  • Cost-savings associated with Warfarin use in AFib patients
    Warfarin use in Medicare patients with nonvalvular atrial fibrillation was independently associated with lower medical costs averaging $9,836 per patient, per year.  
  • Effectiveness of pacemaker/defibrillators to control AFib
    Widespread use of pacemaker/defibrillators to control atrial fibrillation could result in a 50% decrease in stroke.